(329 days)
No
The summary describes a software-controlled suction pump for negative pressure wound therapy. There is no mention of AI, ML, or any related concepts in the intended use, device description, or performance studies. The software control appears to be for managing pressure settings and basic device functions, not for complex data analysis or decision-making typically associated with AI/ML in medical devices.
Yes.
The device description and intended use/indications clearly state that the device is designed to promote wound healing by removing fluids, exudate, and infectious materials through Negative Pressure Wound Therapy (NPWT), applying pressure settings, and being used with dressing kits, all of which are direct therapeutic actions.
No.
Explanation: The device is a suction pump used for wound healing through the removal of fluids and infectious materials (Negative Pressure Wound Therapy), not for diagnosing conditions.
No
The device description explicitly states it is a "software controlled suction device consisting of an electric motor driven, diaphragm, vacuum pump," indicating it includes significant hardware components beyond just software.
Based on the provided text, the RENASYS™ EDGE pump is not an In Vitro Diagnostic (IVD) device.
Here's why:
- IVD Definition: In Vitro Diagnostic devices are used to examine specimens taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening.
- RENASYS™ EDGE Function: The RENASYS™ EDGE pump is a suction device used for Negative Pressure Wound Therapy (NPWT). Its function is to apply negative pressure to a wound to remove fluids and promote healing. It interacts directly with the wound on the patient's body, not with specimens taken from the body for laboratory analysis.
- Intended Use: The intended use clearly describes its application to various wound types on the patient's body.
- Device Description: The description details a mechanical pump that applies suction to a wound.
- Lack of IVD Indicators: The text does not mention any analysis of biological samples, laboratory procedures, or diagnostic purposes related to analyzing specimens.
Therefore, the RENASYS™ EDGE pump is a therapeutic device used for wound management, not an IVD.
N/A
Intended Use / Indications for Use
The RENASYS™ EDGE pump is indicated for patients who would benefit from a suction pump (NPWT), as it may promote wound healing via removal of fluids, including irrigation fluids, wound exudate and infectious materials. Appropriate wound types include:
- Chronic
- · Acute
- · Traumatic
- Sub-acute and dehisced wounds
- · Ulcers (such as pressure or diabetic)
- · Partial-thickness burns
- · Flaps
- Grafts
The RENASYS™ EDGE pump is compatible with the following accessory dressing kits:
- RENASYS™ Foam Dressing Kits
- · RENASYS™ Foam Dressing Kit XL
- · RENASYS™ Gauze Dressing Kits
- · RENASYSTM Abdominal Dressing Kit
- · RENASYS™ Y Connector Kit
- · RENASYSTM White Foam Wound Dressing
When used with the RENASYS™ AB Abdominal Kit with Soft Port, the RENASYS EDGE™ pump is indicated for temporary bridging of abdominal wall openings where primary closure is not possible and/or repeat abdominal entries are necessary. It is intended to be used in open abdominal wounds with exposed viscera, including but not limited to abdominal compartment syndrome. The use of RENASYS™ AB Abdominal Kit with Soft Port is intended for use in acute hospital care settings (trauma, general and plastic surgery wards) and should ideally be applied in the operating theatre.
Product codes
OMP
Device Description
The RENASYS™ EDGE device is a software controlled suction device consisting of an electric motor driven, diaphragm, vacuum pump. The device is designed to provide Negative Pressure Wound Therapy at a range of pressure settings between 25-200mmHg to a closed environment over one or two wounds. The device removes exudate from the wound site(s) to a disposable container, which may promote wound healing via removal of fluids, including irrigation of body fluids, wound exudates and infectious materials.
RENASYS™ EDGE can be operated by either a mains power supply or internal battery. The RENASYS™ EDGE device is compatible with Smith & Nephew RENASYS™ Dressing Kits.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Wounds (including chronic, acute, traumatic, sub-acute, dehisced wounds, ulcers, partial-thickness burns, flaps, grafts), abdominal wall openings, open abdominal wounds with exposed viscera.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Acute hospital care settings (trauma, general and plastic surgery wards), operating theatre.
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification activities were conducted which demonstrate the overall system performance of the RENASYS IM EDGE device is not impacted by the use of RENASYSTM White Foam. The principal test methods used to demonstrate performance were simulated wound model tests to ensure satisfactory performance including fluid management and Negative Pressure Wound Therapy (NPWT) delivery.
- Simulated wound model tests to ensure satisfactory performance including fluid management and Negative Pressure Wound Therapy (NPWT) delivery
- EMC Testing in accordance with IEC 60601-1-2 and RTCA DO-160G ●
- Cybersecurity testing in accordance with FDA guidance "Content of Premarket Submissions for Device Software Functions Guidance for Industry and Food and Drug Administration Staff"
- Software design and testing in accordance with the framework set out in IEC 62304:2006 .
- To support the new environment for use (aircraft), EMC testing (RTCA DO-160G) and NPWT wound model testing was carried out in a low air pressure environment
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4780 Powered suction pump.
(a)
Identification. A powered suction pump is a portable, AC-powered or compressed air-powered device intended to be used to remove infectious materials from wounds or fluids from a patient's airway or respiratory support system. The device may be used during surgery in the operating room or at the patient's bedside. The device may include a microbial filter.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, with the letters "FDA" in a blue square. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
May 24, 2024
Smith & Nephew Medical Ltd Ruby Uttley Senior Regulatory Affairs Specialist 101 Hessle Road Hull, East Riding of Yorkshire HU32BN United Kingdom
Re: K231939
Trade/Device Name: Renasys Edge Regulation Number: 21 CFR 878.4780 Regulation Name: Powered Suction Pump Regulatory Class: Class II Product Code: OMP Dated: September 1, 2023 Received: April 25, 2024
Dear Ruby Uttley:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
1
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
2
For comprehensive regulatory information about mediation-emitting products, including
information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Yu-chieh Chiu -S
Yu-Chieh Chiu, Ph.D. Assistant Director DHT4B: Division of Infection Control and Plastic and Reconstructive Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K231939
Device Name RENASYS™ EDGE
Indications for Use (Describe)
The RENASYS™ EDGE pump is indicated for patients who would benefit from a suction pump (NPWT), as it may promote wound healing via removal of fluids, including irrigation fluids, wound exudate and infectious materials. Appropriate wound types include:
- Chronic
- · Acute
- · Traumatic
- Sub-acute and dehisced wounds
- · Ulcers (such as pressure or diabetic)
- · Partial-thickness burns
- · Flaps
- Grafts
The RENASYS™ EDGE pump is compatible with the following accessory dressing kits:
- RENASYS™ Foam Dressing Kits
- · RENASYS™ Foam Dressing Kit XL
- · RENASYS™ Gauze Dressing Kits
- · RENASYSTM Abdominal Dressing Kit
- · RENASYS™ Y Connector Kit
- · RENASYSTM White Foam Wound Dressing
When used with the RENASYS™ AB Abdominal Kit with Soft Port, the RENASYS EDGE™ pump is indicated for temporary bridging of abdominal wall openings where primary closure is not possible and/or repeat abdominal entries are necessary. It is intended to be used in open abdominal wounds with exposed viscera, including but not limited to abdominal compartment syndrome. The use of RENASYS™ AB Abdominal Kit with Soft Port is intended for use in acute hospital care settings (trauma, general and plastic surgery wards) and should ideally be applied in the operating theatre.
Type of Use (Select one or both, as applicable)
X Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
4
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
5
510(k) Summary
| 21 CFR 807.92 (a)(1): Submitter's Information | |
|---|---|
| 510(k) Owner Name | Smith & Nephew Medical Ltd |
| Address | 101 Hessle Road, Hull, HU3 2BN, United Kingdom |
| Establishment Registration Number | 8043484 |
| Contact Name | Ruby Uttley |
| Telephone Number | +447890 426317 |
| Date Prepared | May 24 2024 |
| 21 CFR 807.92 (a)(2): Device Information | |
| Device Name (Trade/Proprietary Name) | RENASYS™ EDGE |
| Common Name | Negative pressure wound therapy system |
| Review Panel | General and Plastic Surgery |
| Regulation Number | 21 CFR 878.4783 |
| Regulatory Class | Class II |
| Product Code | OMP |
| 21 CFR 807.92 (a)(3): Legally marketed device to which equivalence is claimed | 510(k) Number: K223041 |
| Device Name: RENASYS™ EDGE | |
| 21 CFR 807.92 (a)(4): Device Description |
The RENASYS™ EDGE device is a software controlled suction device consisting of an electric motor driven, diaphragm, vacuum pump. The device is designed to provide Negative Pressure Wound Therapy at a range of pressure settings between 25-200mmHg to a closed environment over one or two wounds. The device removes exudate from the wound site(s) to a disposable container, which may promote wound healing via removal of fluids, including irrigation of body fluids, wound exudates and infectious materials.
RENASYS™ EDGE can be operated by either a mains power supply or internal battery. The RENASYS™ EDGE device is compatible with Smith & Nephew RENASYS™ Dressing Kits.
21 CFR 807.92 (a)(5): Intended Use / Indications for Use
The RENASYSTM EDGE pump is indicated for patients who would benefit from a suction pump (Negative Pressure Wound Therapy), as it may promote wound healing via removal of fluids, including irrigation fluids and body fluids, wound exudate and infectious materials. Appropriate wound types include:
6
- Chronic
- Acute .
- . Traumatic
- Sub-acute and dehisced wounds .
- . Ulcers (such as pressure or diabetic)
- . Partial-thickness burns
- . Flaps
- Grafts .
The RENASYS™ EDGE pump is compatible with the following accessories:
- RENASYS™ Foam Dressing Kits ●
- RENASYS™ Foam Dressing Kit XL
- RENASYS™ Gauze Dressing Kits ●
- RENASYS™ Abdominal Dressing Kit ●
- RENASYS ™Y Connector Kit .
- RENASYSTM White Foam Wound Dressing ●
When used with the RENASYS™ AB Abdominal Kit with Soft Port, the RENASYS™ EDGE pump is indicated for temporary bridging of abdominal wall openings where primary closure is not possible and/or repeat abdominal entries are necessary. It is intended to be used in open abdominal wounds with exposed viscera, including but not limited to abdominal compartment syndrome. The use of RENASYS AB Abdominal Kit with Soft Port is intended for use in acute hospital care settings (trauma, general and plastic surgery wards) and should ideally be applied in the operating theatre.
21 CFR 807.92 (a)(6): Comparison of Technological Characteristics between the Subject and Predicate Devices
The RENASYS™ EDGE device was previously cleared in K223041 with a range of dressing kits. The subject of this application is to add the RENASYS™ White Foam dressing kits as compatible devices (cleared in K213853). No changes have been made to the predicate device to allow for use with the RENASYS™ White Foam dressing kits. A summary of the similarities and differences is included below.
| Predicate Device (K223041) | Subject Device (K231939) | Comparison | |
|---|---|---|---|
| Trade Name: | RENASYSTM EDGE | RENASYSTM EDGE | |
| Intended Use | Same as subject device | Per intended use section | Same |
| Compatible | |||
| Devices | RENASYST™ Foam Dressing Kits | ||
| K142979 | |||
| RENASYST™ Foam Dressing Kit - XL | |||
| K202783 | |||
| RENASYST™ Gauze Dressing Kits | |||
| K142979 | |||
| RENASYSTM Y Connector Kit K181822 | |||
| RENASYSTM Abdominal Dressing Kit | |||
| K143133 (The only kit for use in an open | |||
| abdomen) | RENASYSTM Foam Dressing Kits | ||
| K142979 | |||
| RENASYSTM Foam Dressing Kit – XL | |||
| K202783 | |||
| RENASYST™ Gauze Dressing Kits | |||
| K142979 | |||
| RENASYSTM Y Connector Kit K181822 | |||
| RENASYSTM Abdominal Dressing Kit | |||
| K143133 (The only kit for use in an open | |||
| abdomen) | |||
| RENASYSTM WF White Foam Wound | |||
| Dressing K213853 | Same except the addition | ||
| of RENASYSTM White | |||
| Foam per the scope of | |||
| this submission. | |||
| For both the subject and | |||
| predicate devices, the | |||
| only kit for use with an | |||
| open abdomen is the | |||
| RENASYSTM Abdominal | |||
| Dressing Kit | |||
| Mode of Action | Negative Pressure Wound Therapy | Negative Pressure Wound Therapy | Same |
| Device Operation | Software | Software | Minor updates to |
| Software and Firmware | |||
| to resolve anomalies | |||
| User Interface | Utilizes tactile buttons with soft key | ||
| function | Utilizes tactile buttons with soft key | ||
| function | Same | ||
| Single-use or | |||
| Reusable: | Reusable pump unit, Disposable canister | Reusable pump unit, Disposable canister | Same |
7
| Method of
| Sterilization: | Non-Sterile | Same |
|---|---|---|
| O-Ring | Incorporates O-ring on the canisters | |
| allowing for a new O-ring with each | ||
| therapy | Same | |
| Battery type | Lithium Ion | Same |
| Negative Pressure | 25-200mmHg | Same |
| Therapy Mode | Continuous & Intermittent | Same |
| Alarms | Device utilizes alarms to notify the user of | |
| any loss of therapy | Same | |
| Auto Restart | Incorporates an auto-restart function to re- | |
| initiate therapy if the device has been left | ||
| on pause for more than 1 hour | Same | |
| Wireless | ||
| Technology | Incorporates wireless technology to allow | |
| for Bluetooth connectivity | Same | |
| Configurations | 300ml & 800ml canisters available | Minor manufacturing |
| updates to pump and | ||
| canisters | ||
| Accessories | ||
| Carry Bag | Carry bag for use with device and 300ml | |
| Canister | Same physical product; | |
| labels modified to clarify | ||
| country of origin as USA, | ||
| as well as removal of | ||
| unnecessary European | ||
| regulatory symbols. | ||
| Carry Strap | Carry strap fixes to carry handle | Same physical product; |
| labels modified to clarify | ||
| country of origin as USA, | ||
| as well as removal of | ||
| unnecessary European | ||
| regulatory symbols. |
A range of minor modifications were made to the subject device when compared to the predicate device summarized below:
Technology Changes
- Software and firmware updates to resolve anomalies and update anomaly list .
- . Updates to pump to enhance manufacturability of the device, including addition of exhaust component, a change of material for the foam inside the exhaust box, addition of a label overlay, and addition of an adhesive bead to the interface between the lens and the top trim
- . Updates to canisters, including addition of an odor filter, updating the assembly process so the SAP bag within the canister is no longer attached to the post, and change of the SAP gelling agent weight to 3g to the 300 mL canister
Labeling Changes
- Updated package labeling to include modifications to the EDGE canister, EDGE carry bag and . EDGE carry strap labels
- . Minor updates to the EDGE manuals for clarity
- . Addition of magnetic safety information
- . Addition of cleared, compatible accessories to the Indications for Use (updated in EDGE manuals)
- . Additional EMC User Environment Table for aircraft environment use
21 CFR 807.92 (b)(1): Brief discussion of nonclinical tests submitted/referenced/ relied on in this submission to determine substantial equivalence
Verification activities were conducted which demonstrate the overall system performance of the RENASYS IM EDGE device is not impacted by the use of RENASYSTM White Foam. The principal test methods used to demonstrate performance were simulated wound model tests to ensure satisfactory performance including fluid management and Negative Pressure Wound Therapy (NPWT) delivery.
- Simulated wound model tests to ensure satisfactory performance including fluid management and Negative Pressure Wound Therapy (NPWT) delivery
8
- EMC Testing in accordance with IEC 60601-1-2 and RTCA DO-160G ●
- . Cybersecurity testing in accordance with FDA guidance "Content of Premarket Submissions for Device Software Functions Guidance for Industry and Food and Drug Administration Staff"
- Software design and testing in accordance with the framework set out in IEC 62304:2006 .
- . To support the new environment for use (aircraft), EMC testing (RTCA DO-160G) and NPWT wound model testing was carried out in a low air pressure environment
21 CFR 807.92 (b)(2): Brief discussion of clinical tests submitted/referenced/ relied on in this submission to determine substantial equivalence
No clinical data was provided to support the demonstration of substantial equivalence.
21 CFR 807.92 (b)(3): Conclusions drawn
In establishing substantial equivalence to the predicate device, Smith & Nephew Medical Ltd evaluated the indications for use, principle of operation, materials, technology, product specifications and energy requirements of the device. Performance testing has been completed to demonstrate that the RENASYS™ EDGE device when used with the RENASYS™ White Foam is substantially equivalent to the predicate device for the intended use.